Metformin and ZLN005 prevent NTM-mediated macrophage dysfunction through PGC-1α. by Joel R. Frandsen (20685133)

Subjects:

Metformin and ZLN005 attenuate MAC-mediated mitochondrial membrane potential damage. by Joel R. Frandsen (20685133)

Subjects:

Metformin and ZLN005 facilitate increased phagocytic uptake and intracellular killing of MAB. by Joel R. Frandsen (20685133)

Subjects:

NTM infection induces mitochondrial damage and reduces mitochondria number. by Joel R. Frandsen (20685133)

Subjects:

Exploring Metalloproteome Remodeling in Calprotectin-Stressed Acinetobacter baumannii Using Chemoproteomics by Maximillian K. Osterberg (22514185)

Subjects:

Age-specific incidence trends of HFMD in Guangzhou from 2013 to 2023. by Haipeng Luo (5322419)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Average proportion of first choice female applicants stratified by specialty category. by Lucy Hui (17538542)

Subjects:

Temporal Trends and Forecasting of Hand, Foot, and Mouth Disease. by Haipeng Luo (5322419)

Subjects:

Gender-specific incidence trends of HFMD in Guangzhou from 2013 to 2023. by Haipeng Luo (5322419)

Subjects:

Temporal distribution of HFMD incidence in Guangzhou from 2013 to 2023. by Haipeng Luo (5322419)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Age-specific and gender-specific incidence trends of HFMD in Guangzhou, 2013–2023. by Haipeng Luo (5322419)

Subjects:

Exploring Metalloproteome Remodeling in Calprotectin-Stressed Acinetobacter baumannii Using Chemoproteomics by Maximillian K. Osterberg (22514185)

Subjects:

Gender differences in first choice match outcomes. by Lucy Hui (17538542)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

Exploring Metalloproteome Remodeling in Calprotectin-Stressed Acinetobacter baumannii Using Chemoproteomics by Maximillian K. Osterberg (22514185)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects: